The first approved cervical cancer vaccine in China has been extended to 45 years old

Source: Yigu May 30, 2018 Today (May 29), GlaxoSmithKline announced that according to the results of the technical review by the drug review center of the State Drug Administration, it has been approved to extend the age of recipients of HPV vaccine Cervarix to 45 years old, which has become the only cervical cancer vaccine approved in the mainland of China that can be applied to all women aged 9-45 years In July 2016, Hirsch was officially approved in China, which was also the first HPV vaccine to enter the mainland market at that time Hirsch is a 2-valent cervical cancer vaccine, which can prevent the two most common high-risk HPV types - HPV16 and HPV18 In China, more than 84.5% of cervical cancer cases are related to the continuous infection of these two high-risk HPVs Women in China are infected with high-risk HPV The first peak is from 15 to 24 years old, and the second peak is from 40 to 44 years old The first approved coverage age of Hirsch is from 9 to 25 years old women, who are vaccinated with three injections respectively according to the procedures of 0, 1 and 6 months The price of each dose of vaccine is 585.5 yuan In addition to the bivalent Hirsch, currently, the HPV vaccines that have been listed in China also include bivalent vaccines and bivalent vaccines Mosadon's four price HPV vaccine has been approved for market in May last year It can prevent HPV6, 11, 16 and 18 viruses It covers women aged 20-45, and is still three injections According to the procedures of 0, 2 and 6 months, the vaccination price of each dose is 803.5 yuan Recently, MSD's nine price HPV vaccine was approved rapidly It is suitable for women aged 9-26 and men aged 9-15 to prevent cervical cancer, vulvar cancer, vaginal cancer and anal cancer caused by HPV16, 18, 31, 33, 45, 52 and 58, as well as genital warts caused by HPV6 and 11 On November 11, Hainan Province announced the bid price of the nine price HPV vaccine At the same time, a number of medical institutions in Hong Kong issued a notice saying that they had received a formal notice from the Eastern medicine factory of Mosha to suspend the supply of nine price HPV vaccine to the whole Hong Kong According to relevant reports, the first nine price HPV vaccine will be vaccinated in Boao super Hospital of Hainan tomorrow (May 30) At present, the first batch of 6000 vaccines purchased has reached about 2000 and will be listed in Beijing as soon as the end of this year In addition to MSD, many enterprises in China have entered the nine price market Up to now, the nine price cervical cancer vaccine clinical trials of Xiamen Wantai Canghai Biotechnology Co., Ltd., Shanghai Bowei Biotechnology Co., Ltd and Shanghai Zerun Biotechnology Co., Ltd have been approved At the same time, the nine price cervical cancer vaccine clinical trials of Jiangsu Ruike Biotechnology Co., Ltd The test is still under application Media have estimated that according to the current approval speed of CDE for imported drugs and domestic self-developed new drugs, as well as the on-site instructions of Premier Li Keqiang, the insiders predicted that the imported or domestic nine price HPV vaccine would be fully approved and listed by 2019 at the latest, so as to enrich China's market As of April 18, a total of 12 domestic enterprises have successively applied for the research and development of HPV vaccine to prevent cervical cancer In addition to the 2, 4 and 9 prices, there are 3, 6, 11 and 14 price vaccines The coverage of 11 and 14 price vaccines to cervical cancer is theoretically higher than that of 9 Price vaccines Luo Jianhui, head of biopharmaceutical Department of the national drug review center, said more and more HPV vaccines are expected to be available for public choice in the next few years The specific time for domestic vaccines to go on the market depends on the R & D speed of the enterprise The drug evaluation center shall strengthen communication with the enterprise on R & D application, consider whether there is further time saving, change the previous series connection mode to the parallel optimization mode, and jointly promote the vaccines to reach the technical requirements of the market as soon as possible.